Model Medicines is at the forefront of drug discovery, leveraging its proprietary GALILEO™ platform, which integrates advanced AI technologies to identify and develop novel therapeutics. The platform employs a multimodal approach that combines diverse data inputs, including biophysical assays, patient data, and chemical properties, to navigate the vast biological and chemical landscape. By utilizing sophisticated algorithms such as generative AI models, molecular docking, and deep learning techniques, Model Medicines can explore new chemical spaces and design drug candidates that are structurally dissimilar from existing compounds. This innovative methodology allows the company to focus on high-potential drug candidates, particularly for challenging therapeutic targets that have previously been deemed undruggable.

One of the notable advancements from Model Medicines is the development of MDL-4101, a selective inhibitor targeting the BRD4 protein, which is implicated in various aggressive cancers, including thyroid cancer. The discovery of MDL-4101 exemplifies the company's commitment to addressing significant unmet medical needs through AI-driven drug discovery. By employing its GALILEO™ platform, Model Medicines has successfully identified compounds with optimal pharmacological properties, demonstrating robust anti-tumor activity in preclinical models. This approach not only enhances the efficiency of drug discovery but also aims to deliver best-in-class therapeutics that can transform treatment options for patients facing serious health challenges.

United States

Model Medicines is an AI-driven, human health company using AI to model all of chemistry and human biology, to accelerate the creation of life-changing drugs. 

The company was founded in 2019 to deliver on the promise of AI-Drug discovery. With more than 182 compounds for 26 targets, they are delivering on the promise of AI-drug discovery. The company has developed a robust pipeline of patent-pending therapeutics for oncology, infectious diseases, gastric disorders, neurological disorders, and weight disorders. The company is based in La Jolla, CA.

Model Medicines

Company Details